TriLink BioTechnologies, a subsidiary of Maravai LifeSciences and a global provider of life science reagents and services, has strengthened its international intellectual property portfolio with the issuance of a new patent from the China National Intellectual Property Administration for its CleanCap® Capping Technology.
The patent covers methods of synthesizing RNA molecules using TriLink BioTechnologies' full suite of CleanCap capping analogs, including the latest M6 analog. It includes claims directed to co-transcriptional RNA synthesis methods utilizing trimer or tetramer capping structures. CleanCap technology enables the co-transcriptional production of messenger RNA containing the major natural cap structures found in humans.
The technology has already been deployed in commercially approved COVID-19 mRNA and saRNA vaccines and is currently underpinning drug development programs across a wide range of therapeutic areas, including oncology, infectious diseases, rare diseases, and cell and gene therapies.
Innovative RNA-Capping Technologies
TriLink Biotechnologies® Patents CleanCap® Capping Technology
Trend Themes
-
Precision RNA Capping — Advanced cap analogs are improving mRNA stability and translational efficiency, creating room for differentiated therapeutic platforms with higher potency and cleaner manufacturing profiles.
-
Self-amplifying RNA Therapies — SaRNA systems supported by efficient capping chemistries can enable lower-dose vaccines and treatments, expanding possibilities for scalable and cost-conscious biologic development.
-
Synthetic Biology IP Expansion — Global patent protection around enabling RNA technologies is reshaping competitive advantage, with proprietary synthesis methods becoming critical assets in next-generation medicine.
Industry Implications
-
Biopharmaceuticals — RNA-capping innovations are strengthening pipelines across oncology, infectious disease, rare disease, and immunotherapy by improving the performance of nucleic acid-based drugs.
-
Vaccine Manufacturing — Co-transcriptional capping methods offer production efficiencies that can support faster vaccine scale-up, particularly for pandemic response and personalized immunization models.
-
Cell and Gene Therapy — High-quality synthetic RNA inputs are becoming foundational for engineered cell therapies and gene-editing workflows, opening pathways for more precise and programmable treatments.